drugset / Trial / NCT05673694
To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability, pharmacokinetics and efficacy of EG017 in androgen receptor-positive, estrogen receptor-positive, and human epidermal growth factor receptor-2-negative patients with advanced breast cancer.
Timeline
- Start
- 2023-03-08
- Primary completion
- 2025-11-07
- Completion
- 2026-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EG017 | Unknown | 6 mg | — |
| Subject | EG017 | Unknown | 12 mg | — |
| Subject | EG017 | Unknown | 18 mg | — |
| Subject | EG017 | Unknown | 24 mg | — |